The second event in the Drug Discovery Innovators and Investors (DDII) event series took place on 4 November, 2026, bringing together representatives from across the UK life sciences sector to discuss the opportunities and challenges facing drug discovery and development. Held in London under the theme Technology, Scale, and Capital:… Read More
Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More
When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More
Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More
Dr Sudha Rao is Chief Scientific Officer of Kazia Therapeutics and Senior Group Leader of Gene Regulation and Translational Medicine at the QIMR Berghofer Medical Research Institute. She tells Diana Turner about her career highlights and current research. DT: Can you tell us what you’re working on… Read More
In this contribution to the Fall 2026 issue of DDW, Dr Andrew French PhD, Dr Richard Boyd PhD, Prof Alice Pébay PhD, and Prof Alan Trounson PhD, explore emerging research into NK cell-derived extracellular vesicles (NK-EVs) as a potential therapeutic platform for neurodegenerative disease. Neurodegenerative diseases… Read More
Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More
News round-up for 26-30 October 2026 by Megan Thomas, Multimedia Editor at DDW. This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as four stories that showcase the far reaching impact of artificial intelligence (AI) in drug discovery. The… Read More
In this contribution to the Fall 2026 issue of DDW, Thomas Edwards, Partnering Lead for C-Further, examines why childhood cancer treatments lag behind adult treatments and what needs to change. Childhood cancer is one of the most underserved areas in oncology Cancer remains the leading… Read More
When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More
When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More
Insilico Medicine has achieved the early drug discovery milestone in its multi-year AI-driven drug discovery collaboration with pharmaceutical group Servier. Under the collaboration, the two companies initiated two distinct R&D programmes for oncology on challenging targets leveraging Insilico’s proprietary end-to-end AI platform, Pharma.AI. Target nominations have been… Read More
In this contribution to the Fall 2026 issue of DDW, Jon Rees, Co-Founder and CEO of MitoRx, talks about the journey obesity treatments are taking and where the opportunities lie. Few areas of medicine have been reshaped as fast as the pharmaceutical treatment of obesity. Read More
Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More
Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More
ScionxBio, a preclinical-stage biotechnology company developing next-generation mRNA therapeutics, has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s platform. The agreement brings together the global expertise of Sanofi’s mRNA… Read More
